Anti-HLA DR 抗体 [SPM289] (ab17844)


  • 製品名Anti-HLA DR antibody [SPM289]
    HLA DR 一次抗体 製品一覧
  • 製品の詳細
    Mouse monoclonal [SPM289] to HLA DR
  • アプリケーション適用あり: Flow Cyt, IHC-Pmore details
  • 種交差性
    交差種: Human
  • 免疫原

    Activated human peripheral blood mononuclear cells.

  • エピトープNot determined.
  • ポジティブ・コントロール
    • Tonsil/lymph node


  • 製品の状態Liquid
  • 保存方法Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
  • バッファーPreservative: 0.09% Sodium Azide
    Constituents: BSA, 10mM PBS, pH 7.4
  • Concentration information loading...
  • 精製度Protein A purified
  • ポリ/モノモノクローナル
  • クローン名SPM289
  • アイソタイプIgG2b
  • 研究分野


Our Abpromise guarantee covers the use of ab17844 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
Flow Cyt Use at an assay dependent concentration. ab170192-Mouse monoclonal IgG2b, is suitable for use as an isotype control with this antibody.
IHC-P 1/50.


  • 機能Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.
  • 配列類似性Belongs to the MHC class II family.
    Contains 1 Ig-like C1-type (immunoglobulin-like) domain.
  • 翻訳後修飾Ubiquitinated by MARCH1 or MARCH8 at Lys-244 leading to down-regulation of MHC class II. When associated with ubiquitination of the beta subunit of HLA-DR: HLA-DRB4 'Lys-254', the down-regulation of MHC class II may be highly effective.
  • 細胞内局在Cell membrane. Endoplasmic reticulum membrane. Golgi apparatus > trans-Golgi network membrane. Endosome membrane. Lysosome membrane. Late endosome membrane. The MHC class II complex transits through a number of intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation.
  • Information by UniProt
  • 参照データベース
  • 別名
    • DR alpha chain antibody
    • DR alpha chain precursor antibody
    • DRA_HUMAN antibody
    • DRB1 antibody
    • DRB4 antibody
    • Histocompatibility antigen HLA DR alpha antibody
    • HLA class II histocompatibility antigen antibody
    • HLA class II histocompatibility antigen DR alpha chain antibody
    • HLA DR1B antibody
    • HLA DR3B antibody
    • HLA DRA antibody
    • HLA DRA1 antibody
    • HLA DRB1 antibody
    • HLA DRB3 antibody
    • HLA DRB4 antibody
    • HLA DRB5 antibody
    • HLA-DRA antibody
    • HLADR4B antibody
    • HLADRA1 antibody
    • HLADRB antibody
    • Major histocompatibility complex class II DR alpha antibody
    • Major histocompatibility complex class II DR beta 1 antibody
    • Major histocompatibility complex class II DR beta 3 antibody
    • Major histocompatibility complex class II DR beta 4 antibody
    • Major histocompatibility complex class II DR beta 5 antibody
    • MGC117330 antibody
    • MHC cell surface glycoprotein antibody
    • MHC class II antigen DRA antibody
    • MHC II antibody
    • MLRW antibody
    see all

Anti-HLA DR antibody [SPM289] 画像

  • Human tonsil stained with ab17844.

Anti-HLA DR antibody [SPM289] (ab17844) 使用論文

ab17844 has not yet been referenced specifically in any publications.

Product Wall

Thank you for your enquiry. Since the epitope has not been determined, ab17844 can be considered to be a "general" HLA DR antibody. Please contact us again if you have any additional questions.